Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol

References

• AfonsoASVerhammeKMSturkenboomMCBrusselleGGCOPD in the general population: prevalence, incidence and survivalRespir Med2011105121872188421852081
   PubMed Web of Science ®Google Scholar
• ChapmanKRManninoDMSorianoJBEpidemiology and costs of chronic obstructive pulmonary diseaseEur Resp J2006271188207
   PubMed Web of Science ®Google Scholar
• EisnerMDAnthonisenNCoultasDAn official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2010182569371820802169
   PubMed Web of Science ®Google Scholar
• LibbyAMFishDNHosokawaPWPatient-level medication regimen complexity across populations with chronic diseaseClin Ther201335438539823541707
   PubMed Web of Science ®Google Scholar
• Carr-LopezSMShekALastimosaJMedication adherence behaviors of Medicare beneficiariesPatient Pref Adherence2014812771284
   Web of Science ®Google Scholar
• MedicGHigashiKLittlewoodKJDiezTGranströmOKahnRSDosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysisNeuropsychiatr Dis Treat2013911913123355782
   PubMed Web of Science ®Google Scholar
• CaldeiraDVaz-CarneiroACostaJThe impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysisRev Port Cardiol2014337–843143725070671
   PubMedGoogle Scholar
• ColemanCIRobertsMSSobierajDMLeeSAlamTKaurREffect of dosing frequency on chronic cardiovascular disease medication adherenceCurr Med Res Opin201228566968022429067
   PubMed Web of Science ®Google Scholar
• LalibertéFBookhartBKNelsonWWImpact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolismPatient20136321322423857628
   PubMedGoogle Scholar
• ColemanCILimoneBSobierajDMDosing frequency and medication adherence in chronic diseaseJ Manage Care Pharm2012187527539
   PubMed Web of Science ®Google Scholar
• SainiSDSchoenfeldPKaulbackKDubinskyMCEffect of medication dosing frequency on adherence in chronic diseasesAm J Manage Care2009156e22e33
   PubMed Web of Science ®Google Scholar
• LavoriniFInhaled drug delivery in the hands of the patientJ Aerosol Med Pulm Drug Deliv201427641441825238005
   PubMed Web of Science ®Google Scholar
• NewmanSImproving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug deliveryExpert Opin Drug Deliv201411336537824386924
   PubMed Web of Science ®Google Scholar
• AghTDömötörPBártfaiZInotaiAFujszEMészárosARelationship Between Medication Adherence and Health-Related Quality of Life in Subjects With COPD: A Systematic ReviewRespir Care2014pii respcare.03123
   Google Scholar
• ÁghTInotaiAMészárosÁFactors associated with medication adherence in patients with chronic obstructive pulmonary diseaseRespiration201182432833421454953
   PubMed Web of Science ®Google Scholar
• DolceJJCrispCManzellaBRichardsJMHardinJMBaileyWCMedication adherence patterns in chronic obstructive pulmonary diseaseChest19919948378412009784
   PubMed Web of Science ®Google Scholar
• ViswanathanMGolinCEJonesCDInterventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic reviewAnn Intern Med20121571178579522964778
   PubMed Web of Science ®Google Scholar
• ChrystynHSmallMMilliganGHigginsVGilEGEstruchJImpact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPDRespir Med2014108235836524209768
   PubMed Web of Science ®Google Scholar
• MäkeläMJBackerVHedegaardMLarssonKAdherence to inhaled therapies, health outcomes and costs in patients with asthma and COPDRespir Med2013107101481149023643487
   PubMed Web of Science ®Google Scholar
• BryantJMcDonaldVMBoyesASanson-FisherRPaulCMelvilleJImproving medication adherence in chronic obstructive pulmonary disease: a systematic reviewRespir Res20131410924138097
   PubMed Web of Science ®Google Scholar
• CharlesMSBlanchetteCMSilverHLavalleeDDalalAAMapelDAdherence to controller therapy for chronic obstructive pulmonary disease: a reviewCurr Med Res Opin201026102421242920815661
   PubMed Web of Science ®Google Scholar
• MendysPZulligLLBurkholderRGrangerBBBosworthHBMedication adherence: process for implementationPatient Prefer Adherence201481025103425114513
   PubMed Web of Science ®Google Scholar
• ToyELBeaulieuNUMcHaleJMTreatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med2011105343544120880687
   PubMed Web of Science ®Google Scholar
• YuAPGuérinAde LeonDPClinical and economic outcomes of multiple versus single long-acting inhalers in COPDRespir Med2011105121861187121807487
   PubMed Web of Science ®Google Scholar
• TashkinDPMultiple dose regimens. Impact on complianceChest19951075 Suppl176S182S7743823
   PubMed Web of Science ®Google Scholar
• RascatiKLAkazawaMJohnsrudMStanfordRHBlanchetteCMComparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimenClin Ther20072961203121317692734
   PubMed Web of Science ®Google Scholar
• Olszanecka-GlinianowiczMAlmgren-RachtanAThe adherence and illness perception of patients diagnosed with asthma or chronic obstructive pulmonary disease treated with polytherapy using new generation CyclohalerPostepy Dermatol Alergol201431423524625254009
   PubMed Web of Science ®Google Scholar
• DeleaTEHagiwaraMDalalAAStanfordRHBlanchetteCMHealthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapiesCurr Med Res Opin200925111319210134
   PubMed Web of Science ®Google Scholar
• BlanchetteCMGrossNJAltmanPRising Costs of COPD and the Potential for Maintenance Therapy to Slow the TrendAm Health Drug Benefits2014729810624991394
   PubMedGoogle Scholar
• KewKMMavergamesCWaltersJALong-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201310CD01017724127118
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• FeldmanGJBernsteinJAHamiltonANivensMCKorduckiLLaForceCThe 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studiesSpringerplus2014341925187881
   PubMedGoogle Scholar
• OhnoTWadaSHanadaSSawaguchiHMurakiMTohdaYEfficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferencesInt J Chron Obstruct Pulm Dis20149107114
   PubMed Web of Science ®Google Scholar
• PriceDGrayAGaleRCost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPDRespir Med2011105111635164721764277
   PubMed Web of Science ®Google Scholar
• RoskellNSAnzuetoAHamiltonADisseBBeckerKOnce-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterolInt J Chron Obstruct Pulm Dis20149813824
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMed Web of Science ®Google Scholar
• KeamSJKeatingGMTiotropium bromide. A review of its use as maintenance therapy in patients with COPDTreat Respir Med20043424726815350163
   PubMedGoogle Scholar
• HalpernRBakerCLSuJOutcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary diseasePatient Prefer Adherence2011537538821845037
   PubMed Web of Science ®Google Scholar
• FriedmanMMenjogeSSAntonSFKestenSHealthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD)Pharmacoeconomics2004221174174915250751
   PubMed Web of Science ®Google Scholar
• BosciaJAPudiKKZvarichMTSanfordLSiedererSKCrimCEffect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover studyClin Ther20123481655166622789766
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trialRespir Med2013107455055923332861
   PubMed Web of Science ®Google Scholar
• LötvallJBakkePSBjermerLEfficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trialBMJ Open201221e000370
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• DonohueJFAnzuetoABrooksJMehtaRKalbergCCraterGA randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDRespir Med2012106797097922498110
   PubMed Web of Science ®Google Scholar
• CahnATal-SingerRPouliquenIJSafety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studiesClin Drug Invest2013337477488
   PubMed Web of Science ®Google Scholar
• DecramerMMaltaisFFeldmanGBronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patientsRespir Physiol Neurobiol2013185239339923026438
   PubMed Web of Science ®Google Scholar
• VinckenWAumannJChenHHenleyMMcBryanDGoyalPEfficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 studyInt J Chron Obstruct Pulm Dis20149215228
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Resp J201342614841494
   PubMed Web of Science ®Google Scholar
• RodrigoGJPlazaVEfficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic reviewChest2014146230931724556877
   PubMed Web of Science ®Google Scholar
• PriceDKeiningerDCosta-ScharplatzMCost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare settingRespir Med2014108121786179325307414
   PubMed Web of Science ®Google Scholar
• BatemanEDMahlerDAVogelmeierCFWedzichaJAPatalanoFBanerjiDRecent advances in COPD disease management with fixed-dose long-acting combination therapiesExpert Rev Respir Med20148335737924802656
   PubMed Web of Science ®Google Scholar
• ScottLJHairPUmeclidinium/Vilanterol: first global approvalDrugs201474338939524532124
   PubMed Web of Science ®Google Scholar
• CelliBCraterGKilbrideSOnce-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled studyChest2014145981991
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
   PubMed Web of Science ®Google Scholar
• FeldmanGWalkerRRBrooksJMehtaRCraterG28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trialPulmon Pharmacol Ther2012256465471
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res2014157825015176
   PubMed Web of Science ®Google Scholar
• GoyalNBeeraheeMKalbergCChurchAKilbrideSMehtaRPopulation pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary diseaseClin Pharmacokinet201453763764824756395
   PubMed Web of Science ®Google Scholar
• KelleherDLMehtaRSJean-FrancoisBMSafety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trialPloS One2012712e5071623284643
   PubMed Web of Science ®Google Scholar
• MehtaRHardesKKelleherDPreeceATombsLBrealeyNEffects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized studyClin Ther20143671016102724947493
   PubMed Web of Science ®Google Scholar
• KelleherDTombsLPreeceABrealeyNMehtaRA randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjectsPulm Pharmacol Ther2014291495725020273
   PubMed Web of Science ®Google Scholar
• MalerbaMMorjariaJBRadaeliADifferential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterolInt J Chron Obstruct Pulmon Dis2014968769525061288
   PubMed Web of Science ®Google Scholar